NCT07030257 - Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

August 15, 2028

Study Completion Date

February 28, 2029

Conditions

Solid Tumor MalignanciesColorectal CarcinomaSmall Cell Lung Cancer ( SCLC )Head and Neck (HNSCC)Bladder CancerNon-Small Cell Lung CancerPancreatic Cancer, Advanced or Metastatic

Interventions

DRUG

CP-383

Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells

Trial Locations (7)

22031

RECRUITING

NEXT Virginia, Fairfax

28078

RECRUITING

Carolina BioOncology Institute, Huntersville

43537

RECRUITING

Taylor Cancer Research Center, Maumee

68130

RECRUITING

Nebraska Cancer Specialists, Omaha

75039

RECRUITING

NEXT Oncology - Dallas, Dallas

78229

NOT_YET_RECRUITING

START San Antonio, San Antonio

84119

RECRUITING

START Mountain Region, West Valley City